Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11919910 Spiropyrrolidine derived antiviral agents

Patent 11919910 was granted and assigned to Enanta Pharmaceuticals on March, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Enanta Pharmaceuticals

0

Current Assignee

Enanta Pharmaceuticals

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Xuechao Xing0

Guoqiang Wang0

Matthew C. Rhodes0

Yat Sun Or0

Yong He0

Ruichao Shen0

Date of Patent

March 5, 2024

0

Patent Application Number

179834740

Date Filed

November 9, 2022

0

Patent Citations

US Patent 9290757 Protease screening methods and proteases identified thereby

0

US Patent 8222288 Small molecule inhibitors of MDM2 and the uses thereof

0

US Patent 8222425 Organic compounds and their uses

0

US Patent 8372802 Fluorinated macrocyclic compounds as hepatitis C virus inhibitors

0

US Patent 11124497 Inhibitors of cysteine proteases and methods of use thereof

0

US Patent 11174231 Inhibitors of cysteine proteases and methods of use thereof

0

US Patent 11207370 Peptidomimetics for the treatment of coronavirus and picornavirus infections

0

US Patent 11319325 Macrocyclic spiropyrrolidine derived antiviral agents

0

...

Patent Primary Examiner

Joseph R Kosack

0

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11919910 Spiropyrrolidine derived antiviral agents

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool